The atopic dermatitis trial landscape in 2026
Atopic dermatitis is one of the most competitive therapeutic areas in immunology-driven drug development. Dupilumab's commercial success, blockbuster revenues exceeding $10B annually, has attracted every major immunology company to the space. The result is a dense, complex trial landscape with overlapping mechanisms, pediatric extensions, and aggressive head-to-head programs.
For dermatology pharma and biotech teams, keeping up with new trial registrations across IL-4/IL-13, JAK inhibitors, OX40, TSLP, IL-31, and emerging mechanisms requires systematic monitoring. DataLookout automates this work.
Get daily atopic dermatitis trial digest
Every new biologic, JAK inhibitor, and topical trial, in your inbox each morning.
Sign Up FreeA primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the… NCT07355075 | Primary completion moved at least 6 months later Primary endpoints added | Recruiting |
15 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In… NCT05995964 | Oct 19, 2026 · Estimated | Phase 2 |
29 more on the Completions page. See the calendar →
Key mechanisms generating new atopic dermatitis trials
IL-4/IL-13 dual inhibition and selective targeting
Following dupilumab (IL-4Rα), the second wave targets related cytokines with higher selectivity or improved dosing profiles. Programs include:
- Subcutaneous anti-IL-13 antibodies with monthly or less frequent dosing
- Next-generation IL-4Rα antibodies with extended half-life and self-injection devices
- Tralokinumab (IL-13 selective) follow-on combination studies
- Bispecifics combining IL-4/IL-13 with TSLP or OX40L blockade
JAK inhibitors: oral and topical
Three JAK inhibitors are approved for moderate-to-severe AD (baricitinib, upadacitinib, abrocitinib). New trial activity focuses on:
- JAK1-selective inhibitors with improved tolerability profiles
- Topical JAK inhibitors for mild-to-moderate disease (ruxolitinib cream approved; new entrants in development)
- Combination of oral JAK inhibitors with dupilumab for refractory patients
- Long-term safety extensions and real-world evidence studies
OX40 and OX40L: memory T cell targeting
OX40 pathway blockade addresses AD at the memory T cell level, potentially offering longer disease modification. Rocatinlimab (anti-OX40) is in late-stage development; amlitelimab (anti-OX40L) has shown Phase 3 data. New trials are exploring:
- Combination with IL-4/IL-13 inhibitors for refractory patients
- OX40 in pediatric populations and prevention studies
- Long-term maintenance and treatment-free remission protocols
TSLP and IL-33 upstream inhibition
Tezepelumab (anti-TSLP) showed modest activity in AD; next-generation TSLP and IL-33 programs are testing higher dose levels, pediatric populations, and combination strategies. Itepekimab (anti-IL-33) has an active AD program.
Novel topical and non-systemic approaches
For mild-to-moderate AD, the development pipeline has expanded beyond TCS/TCI to include:
- PDE4 inhibitors (crisaborole follow-ons with improved potency and tolerability)
- Aryl hydrocarbon receptor (AhR) modulators: tapinarof approved; next-generation compounds in trials
- IL-31 antagonists targeting itch specifically (nemolizumab Phase 3)
- Microbiome-targeted approaches (Staphylococcus aureus decolonization strategies)
Who monitors atopic dermatitis clinical trials?
- Dermatology business development and competitive intelligence teams at companies with AD pipelines tracking competitor enrollment and mechanism status
- Clinical development leaders designing new AD trials who need a comprehensive view of what's running in the space
- Medical affairs and MSL teams at companies with marketed AD therapies needing current competitor trial data
- Healthcare analysts covering dermatology-focused biotech and pharmaceutical companies
- Pediatric dermatologists needing to know what trials are enrolling for children with moderate-to-severe AD
Start monitoring atopic dermatitis trials today
Set your keywords once. Get daily updates automatically. Free tier available.
Get Started FreeRelated immunology and dermatology trial monitors
- Rheumatoid arthritis clinical trials: overlapping JAK inhibitor programs and shared biologics platforms
- Lupus clinical trials: shared immunology mechanisms, type I interferon biology
- Crohn's disease clinical trials: shared IL-23, JAK, and TL1A programs across immunology
342 active trials, 180 recruiting.
Industry sponsors run 186 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 102.
| Top industry sponsor | Active trials |
|---|---|
| Sanofi / Regeneron | 14 |
| Pfizer | 13 |
| AbbVie | 10 |
| Keymed Biosciences Co.Ltd | 5 |
| Almirall, S.A. | 4 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Allergy, Asthma, and Atopic Eczema in Finland NCT06330974 | Not Yet Recruiting | Interventions modified | 2026-10-16 |
| A Phase III Study of GS101 Injection to Dupixent® NCT07386743 | Recruiting | Recruitment opened | 2026-10-16 |
| A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in… NCT07754786 | Recruiting | Recruitment opened | 2026-10-16 |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With… NCT07765888 | Recruiting | Trial sites expanded: 3 → 21 locations | 2026-10-16 |
| A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema NCT07216027 | Recruiting | Trial sites expanded: 33 → 42 locations | 2026-10-14 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top 2 trials), the weekly report (top 3 trials). No credit card.
Pro, $49/month or $490/year: 10 sponsor + 10 disease watchlists, 10 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list, Completions calendar, the full weekly report, landscape reports, CSV export.